Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) Shares Outstanding (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Shares Outstanding data on record, last reported at $132.0 million in Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 77.6% to $132.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $132.0 million, a 77.6% increase, with the full-year FY2025 number at $131.7 million, up 89.86% from a year prior.
  • Shares Outstanding reached $132.0 million in Q1 2026 per IKT's latest filing, roughly flat from $131.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for IKT hit a ceiling of $132.0 million in Q1 2026 and a floor of $12000.0 in Q3 2023.
  • A 5-year average of $36.0 million and a median of $6.5 million in 2024 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: tumbled 99.72% in 2023, then skyrocketed 62100.58% in 2024.
  • Tracing IKT's Shares Outstanding over 5 years: stood at $4.2 million in 2022, then skyrocketed by 46.45% to $6.2 million in 2023, then skyrocketed by 1021.23% to $69.4 million in 2024, then skyrocketed by 89.86% to $131.7 million in 2025, then rose by 0.26% to $132.0 million in 2026.
  • Business Quant data shows Shares Outstanding for IKT at $132.0 million in Q1 2026, $131.7 million in Q4 2025, and $74.8 million in Q3 2025.